Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

55.00 +1.00 (+1.85%)
Streaming Delayed Price Updated: 1:33 PM EDT, Jun 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Expert Ratings For Arcellx
Via Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
Analyst Expectations For Arcellx's Future
Via Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
Peering Into Arcellx's Recent Short Interest
Via Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday. 
Via Benzinga
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
Via Benzinga
Where Arcellx Stands With Analysts
Via Benzinga
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry. 
Via InvestorPlace
Exposures Product Safety
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or  
Via Benzinga
Chart Of The Day: Arcellx - Reimagining Cell Therapy
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. 
Via Talk Markets
3 Biotech Stocks That Could Be Multibaggers in the Making
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily
Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?
Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refra 
Via Benzinga
7 Biotech Stocks to Get In Now Before Investors Catch On
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program. 
Via Benzinga
Exposures Product Safety
FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2  
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.